These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 14603351)
1. Antiangiogenesis: the fifth cancer treatment modality? Camp-Sorrell D Oncol Nurs Forum; 2003; 30(6):934-44. PubMed ID: 14603351 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and cancer: recent advances. Cáceres W; González S P R Health Sci J; 2003 Jun; 22(2):149-51. PubMed ID: 12866139 [TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis and antiangiogenic cancer therapy]. Pour L; Hájek R; Buchler T; Maisnar V; Smolej L Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808 [TBL] [Abstract][Full Text] [Related]
5. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use]. Plavetić ND; Letilović T; Vrbanec D Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217 [TBL] [Abstract][Full Text] [Related]
6. The combination of antiangiogenic therapy with other modalities. O'Reilly MS Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706 [TBL] [Abstract][Full Text] [Related]
7. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Gagne P; Akalu A; Brooks PC Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663 [TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis with integrative cancer therapies. Yance DR; Sagar SM Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711 [TBL] [Abstract][Full Text] [Related]
10. The interaction of radiation therapy and antiangiogenic therapy. O'Reilly MS Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of the tumor vasculature. Tozer GM; Bicknell R Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865 [TBL] [Abstract][Full Text] [Related]
12. Current development status of small-molecule vascular disrupting agents. Chaplin DJ; Horsman MR; Siemann DW Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022 [TBL] [Abstract][Full Text] [Related]
14. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Yang F; Jin C; Jiang YJ; Li J; Di Y; Fu DL Expert Rev Anticancer Ther; 2011 Apr; 11(4):541-9. PubMed ID: 21504321 [TBL] [Abstract][Full Text] [Related]
15. Current strategies and future directions of antiangiogenic tumor therapy. Zhang ZL; Wang JH; Liu XY Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202 [TBL] [Abstract][Full Text] [Related]
16. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163 [TBL] [Abstract][Full Text] [Related]
17. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis. Bahramsoltani M; Plendl J APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849 [TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis in melanoma. Marneros AG Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595 [TBL] [Abstract][Full Text] [Related]
19. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. Ademuyiwa FO; Miller KD Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S151-6. PubMed ID: 19158035 [TBL] [Abstract][Full Text] [Related]